OPtimal Type 2 dIabetes Management Including benchmarking and Standard treatment in CEEMEA - OPTIMISE

Study identifier:NIS-CME-XXX-2012/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA (OPTIMISE)

Medical condition

Diabetes Mellitus, Non-Insulin-Dependent

Phase

N/A

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

733

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Nov 2012

Primary Completion Date: 01 Mar 2014

Study Completion Date: 01 Mar 2014

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Dec 2014 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Patients with diabetes type 2	-

Documents available

NIS-CME-XXX-2012_1_CSR_Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Investigators

Principal Investigator

Dan Isacoff

University of Medicine and Pharmacy Carol Davila, Bucharest, Romania